ES2278702T3 - Composicion para el tratamiento de metastasis o del cancer, que contiene fluorouracilo y un agente de transferencia de metilol. - Google Patents
Composicion para el tratamiento de metastasis o del cancer, que contiene fluorouracilo y un agente de transferencia de metilol. Download PDFInfo
- Publication number
- ES2278702T3 ES2278702T3 ES01309983T ES01309983T ES2278702T3 ES 2278702 T3 ES2278702 T3 ES 2278702T3 ES 01309983 T ES01309983 T ES 01309983T ES 01309983 T ES01309983 T ES 01309983T ES 2278702 T3 ES2278702 T3 ES 2278702T3
- Authority
- ES
- Spain
- Prior art keywords
- cancer
- taurolidine
- treatment
- transfer agent
- taurultam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 18
- 201000011510 cancer Diseases 0.000 title claims abstract description 9
- 206010027476 Metastases Diseases 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- 230000009401 metastasis Effects 0.000 title description 2
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 22
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004267 taurolidine Drugs 0.000 claims abstract description 18
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229950007343 taurultam Drugs 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 abstract description 4
- 230000004614 tumor growth Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 12
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000003079 ectropion Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25313800P | 2000-11-28 | 2000-11-28 | |
| US253138P | 2000-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2278702T3 true ES2278702T3 (es) | 2007-08-16 |
Family
ID=22959032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01309983T Expired - Lifetime ES2278702T3 (es) | 2000-11-28 | 2001-11-28 | Composicion para el tratamiento de metastasis o del cancer, que contiene fluorouracilo y un agente de transferencia de metilol. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20020111328A1 (enExample) |
| EP (1) | EP1208840B1 (enExample) |
| JP (2) | JP2002326936A (enExample) |
| AT (1) | ATE352307T1 (enExample) |
| CA (1) | CA2363973C (enExample) |
| DE (1) | DE60126225T2 (enExample) |
| ES (1) | ES2278702T3 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8304390B2 (en) | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US7345039B2 (en) | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| US6753328B2 (en) * | 2001-10-01 | 2004-06-22 | Rhode Island Hospital | Methods of inhibiting metastases |
| US20100151004A1 (en) * | 2007-03-07 | 2010-06-17 | University Of Medicine And Dentistry Of New Jersey | Modulation of drug sensitivity |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| CN113347976A (zh) * | 2018-08-28 | 2021-09-03 | 科医公司 | 用牛磺罗定水解产物进行的神经母细胞瘤治疗 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015108D0 (en) * | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
| GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
| US6479481B1 (en) * | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
-
2001
- 2001-11-26 CA CA002363973A patent/CA2363973C/en not_active Expired - Fee Related
- 2001-11-27 JP JP2001361167A patent/JP2002326936A/ja active Pending
- 2001-11-27 US US09/993,896 patent/US20020111328A1/en not_active Abandoned
- 2001-11-28 AT AT01309983T patent/ATE352307T1/de not_active IP Right Cessation
- 2001-11-28 EP EP01309983A patent/EP1208840B1/en not_active Expired - Lifetime
- 2001-11-28 DE DE60126225T patent/DE60126225T2/de not_active Expired - Lifetime
- 2001-11-28 ES ES01309983T patent/ES2278702T3/es not_active Expired - Lifetime
-
2009
- 2009-10-09 JP JP2009235501A patent/JP2010043115A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010043115A (ja) | 2010-02-25 |
| JP2002326936A (ja) | 2002-11-15 |
| CA2363973A1 (en) | 2002-05-28 |
| ATE352307T1 (de) | 2007-02-15 |
| DE60126225D1 (de) | 2007-03-15 |
| DE60126225T2 (de) | 2007-10-11 |
| US20020111328A1 (en) | 2002-08-15 |
| CA2363973C (en) | 2009-03-10 |
| EP1208840A2 (en) | 2002-05-29 |
| EP1208840B1 (en) | 2007-01-24 |
| EP1208840A3 (en) | 2003-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7910580B2 (en) | Enhancement of effectiveness of 5-Fluorouracil in treatment of tumor metastases and cancer | |
| ES2762250T3 (es) | Tratamiento combinado del cáncer | |
| ES2251939T3 (es) | Usos y composiciones para tratar tumores primarios y secundarios del sistema nervioso central (cns). | |
| JP2010043115A (ja) | 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強 | |
| ES2255287T3 (es) | Composiciones para el tratamiento de la leucemia linfocitica cronica. | |
| RU2306933C2 (ru) | Улучшенная схема применения противоопухолевого соединения в терапии рака | |
| ES2314470T3 (es) | Combinacion de et-743 con un profarmaco de 5-fluorouracilo para el tratamiento del cancer. | |
| ES2333348T3 (es) | Combinaciones que comprenden epotilonas e inhibidores de la proteina tirosina quinasa y usos farmaceuticos de las mismas. | |
| ES2340021T3 (es) | Tratamiento del carcinoma renal metastatico. | |
| JP2009536956A (ja) | 抗癌治療法 | |
| ES2312978T3 (es) | Potenciador del efecto antitumoral y agente antitumoral. | |
| TW202435896A (zh) | 包含阿茲夫定和化療試劑的抗腫瘤藥物組合物 | |
| JP2007511509A (ja) | Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法 | |
| BG98825A (bg) | Използване на креатин фосфат или фосфоенолпирогроздена киселина за лечение на тумори | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| ES2393398T3 (es) | Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer | |
| WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
| JP2011514355A5 (enExample) | ||
| KR20070089158A (ko) | 암의 치료를 위한ｎ-(3-메톡시-5-메틸피라진-2-일)-2-(4-[1,3,4-옥사디아졸-2-일]페닐)피리딘-3-설폰아미드 및 항-유사분열제의 조합물 | |
| KR100844477B1 (ko) | 항종양 효과 증강제, 항종양제 및 암 치료 방법 | |
| KR20060036058A (ko) | 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물 | |
| Mori | An outline of RAFP therapy | |
| HK1179882A (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
| HK1104780A (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
| MXPA06005359A (en) | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |